how can your practice improve access to anti-sars-cov-2 monoclonal antibodies?
Published 2 years ago • 23 plays • Length 6:21Download video MP4
Download video MP3
Similar videos
-
18:44
optimizing access to monoclonal antibodies for covid-19 infection: the global perspective
-
18:48
optimizing access to monoclonal antibodies for covid-19: us perspective
-
5:00
anti-sars-cov-2 monoclonal antibodies, pre-exposure prophylaxis, and the omicron variant: 22 update
-
6:09
what does ba.2 mean for anti-sars-cov-2 monoclonal antibodies?
-
33:35
challenges and opportunities in the use of monoclonal antibody therapy for covid-19
-
7:06
real-world best practices in a covid-19 clinic
-
1:59:52
practices for improving the use of covid-19 monoclonal antibodies
-
0:56
anti-sars-cov-2 neutralizing monoclonal antibodies: clinical pipeline | rtcl.tv
-
2:42
minimizing patient risks from covid-19: an update on monoclonal antibody therapies
-
5:08
how has the ba.2.12.1 covid-19 subvariant changed clinical practice?
-
5:41
the effect of bq.1 and bq.1.1 on covid-19 treatment
-
8:32
what does the future of anti-sars-cov-2 monoclonal antibodies look like?
-
55:43
picking the best antibody therapeutic candidates to develop the most effective covid-19 therapeutic
-
46:12
covid-19 insights: monoclonal antibodies
-
16:11
sars-cov-2 variants and monoclonal antibodies: what do we know?
-
1:25:02
putting the brakes on sars cov 2: neutralizing antibodies
-
1:27:03
engineering optimized anti sars cov 2 antibody therapeutics
-
3:49
equitable access to monoclonal antibody treatmentfor covid-19
-
59:16
monoclonal antibodies for covid-19: who, when, and how?